Cargando…

Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

OBJECTIVE: To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. METHODS: In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Wenxin, Zhang, Xinyang, Sun, Si, Wang, Qiaohong, Li, Congcong, Zhang, Xiaoxin, Zhao, Aimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495441/
https://www.ncbi.nlm.nih.gov/pubmed/34620101
http://dx.doi.org/10.1186/s12884-021-04161-1
_version_ 1784579553380794368
author Bai, Wenxin
Zhang, Xinyang
Sun, Si
Wang, Qiaohong
Li, Congcong
Zhang, Xiaoxin
Zhao, Aimin
author_facet Bai, Wenxin
Zhang, Xinyang
Sun, Si
Wang, Qiaohong
Li, Congcong
Zhang, Xiaoxin
Zhao, Aimin
author_sort Bai, Wenxin
collection PubMed
description OBJECTIVE: To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. METHODS: In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet. RESULTS: Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80 ± 0.22 IU/ml vs. 0.61 ± 0.24 IU/ml; P <  0.0001), although most patients in the three groups reached the target concentration of anti-Xa. Furthermore, patients in the enoxaparin group had a more stable anti-Xa levels during pregnancy. In addition, patients in the nadroparin group had a higher rate of local allergy than those in the enoxaparin group (60.5% vs. 42.5%; P = 0.004) and those in the dalteparin group (60.5% vs. 33.3%; P = 0.002). Further examination by the type of local allergy indicated a dramatic difference in pruritus and induration between the nadroparin group and the other two groups. No difference was found in the incidence of liver and renal dysfunction and thrombocytopenia. CONCLUSION: Compared with nadroparin and daltepatin, enoxaparin showed a better performance regarding anti-Xa levels and the incidence of adverse reactions in the treatment of RSA.
format Online
Article
Text
id pubmed-8495441
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84954412021-10-07 Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study Bai, Wenxin Zhang, Xinyang Sun, Si Wang, Qiaohong Li, Congcong Zhang, Xiaoxin Zhao, Aimin BMC Pregnancy Childbirth Research OBJECTIVE: To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. METHODS: In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet. RESULTS: Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80 ± 0.22 IU/ml vs. 0.61 ± 0.24 IU/ml; P <  0.0001), although most patients in the three groups reached the target concentration of anti-Xa. Furthermore, patients in the enoxaparin group had a more stable anti-Xa levels during pregnancy. In addition, patients in the nadroparin group had a higher rate of local allergy than those in the enoxaparin group (60.5% vs. 42.5%; P = 0.004) and those in the dalteparin group (60.5% vs. 33.3%; P = 0.002). Further examination by the type of local allergy indicated a dramatic difference in pruritus and induration between the nadroparin group and the other two groups. No difference was found in the incidence of liver and renal dysfunction and thrombocytopenia. CONCLUSION: Compared with nadroparin and daltepatin, enoxaparin showed a better performance regarding anti-Xa levels and the incidence of adverse reactions in the treatment of RSA. BioMed Central 2021-10-07 /pmc/articles/PMC8495441/ /pubmed/34620101 http://dx.doi.org/10.1186/s12884-021-04161-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bai, Wenxin
Zhang, Xinyang
Sun, Si
Wang, Qiaohong
Li, Congcong
Zhang, Xiaoxin
Zhao, Aimin
Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title_full Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title_fullStr Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title_full_unstemmed Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title_short Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
title_sort effect of low-molecular-weight heparins on anti-xa peak levels and adverse reactions in chinese patients with recurrent spontaneous abortion: a single-center, observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495441/
https://www.ncbi.nlm.nih.gov/pubmed/34620101
http://dx.doi.org/10.1186/s12884-021-04161-1
work_keys_str_mv AT baiwenxin effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT zhangxinyang effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT sunsi effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT wangqiaohong effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT licongcong effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT zhangxiaoxin effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy
AT zhaoaimin effectoflowmolecularweightheparinsonantixapeaklevelsandadversereactionsinchinesepatientswithrecurrentspontaneousabortionasinglecenterobservationalstudy